18F-FDG-PET/CT in the surveillance of patients with lymphoma: Detection of asymptomatic recurrences;PET-TAC con 18F-FDG en el seguimiento de pacientes con linfoma: Detección de recidivas asintomáticas

Revista Espanola de Medicina Nuclear e Imagen Molecular

Volumn 31, Issue 1, 2012, Pages 22-27

  Garcia Vicente A M ^a   Bellon Guardia M ^a   Soriano Castrejon A ^a   Calle Primo, C ^a   Cordero Garcia J M ^a   Palomar Munoz A ^a   Pilkington Woll, J P ^a   Talavera Rubio, M P ^a   Hernandez Ruiz B ^a  

^a Hospital General Universitario   (Spain)

Author keywords

18F FDG; Asymptomatic recurrence; Linfoma; Lymphoma; PET TAC; PET CT; Recidiva asintom tica; Seguimiento; Surveillance

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; LABORATORY DIAGNOSIS; LONGITUDINAL STUDY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; NONHODGKIN LYMPHOMA; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; ASYMPTOMATIC DISEASE; HEALTH SURVEY; MIDDLE AGED; SCINTISCANNING; TUMOR RECURRENCE;

ADULT; ASYMPTOMATIC DISEASES; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LONGITUDINAL STUDIES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POPULATION SURVEILLANCE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 84864315246     PISSN: 2253654X     EISSN: 22538070     Source Type: Journal    
DOI: 10.1016/j.remn.2011.04.009     Document Type: Article

References (28)

1. Seshadri T., Kuruvilla J., Crump M., Keating A. Salvage therapy for relapsed/refractory diffuse large B cell lymphoma. Biol Blood Marrow Transplant 2008, 14:259-267.
2. Hamlin P.A., Zelenetz A.D., Kewalramani T., Qin J., Satagopan J.M., Verbel D., et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003, 102:1989-1996.
3. Torrey M.J., Poen J.C., Hoppe R.T. Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol 1997, 15:1123-1130.
4. Radford J.A., Eardley A., Woodman C., Crowther D. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests?. A review of hospital records. Br Med J 1997, 314:343-346.
5. Weeks J.C., Yeap B.Y., Canellos G.P., Shipp M.A. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 1991, 9:1196-1203.
6. Talavera Rubio M.P., García Vicente A.M., Domínguez Ferreras E., Calle Primo C., Poblete García V.M., Hernández Ruiz B., et al. PET-TAC con contraste intravenoso en la valoración de pacientes con linfoma. Aproximación hacia las indicaciones diagnósticas. Rev Esp Med Nucl 2009, 28:235-244.
7. 18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma. J Clin Oncol 2009, 27:1781-1787.
8. Zinzani P.L., Tani M., Trisolini R., Fanti S., Stefoni V., Alifano M., et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica 2007, 92:771-777.
9. 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma. Ann Hematol 2009, 88:1229-1236.
10. Jerusalem G., Beguin Y., Fassotte M.F., Belhocine T., Hustinx R., Rigo P., et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003, 14:123-130.
11. 18F-fluorodesoxiglucosa. Rev Esp Med Nucl 2009, 28:85-89.
12. 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun 2005, 26:689-694.
13. Hasenclever D., Diehl V. A pronostic score for advance Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's disease. N Engl J Med 1998, 339:1506-1514.
14. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-94.
15. Schaefer H.G., Taverna C., Strobel K., Wastl C., Kurrer M., Hany T.F., et al. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy-is biopsy of FDG-avid lesions still needed?. Radiology 2007, 244:257-262.
16. Levine J.M., Weiner M., Kelly K.M. Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol 2006, 28:711-714.
17. Meany H.J., Gidvani V.K., Minniti C.P. Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer 2007, 48:399-402.
18. Sonet A., Graux C., Nollevaux N.C., Krug B., Bosly A., Vander Borght T. Unsuspected FDGPET findings in the follow-up of patients with lymphoma. Ann Hematol 2007, 86:9-15.
19. Rhodes M.M., Delbeke D., Whitlock J.A., Martin W., Kuttesch J.F., Frangoul H.A., et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol 2006, 28:300-306.
20. Petrausch U., Samaras P., Veit-Haibach P., Tschopp A., Soyka J.D., Knuth A., et al. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?. Ann Oncology 2010, 21:1053-1057.
21. 18F-FDG PET monitoring of tumour response to chemotherapy: 18F FDG uptake correlate with the viable tumour cell fraction?. Eur J Nucl Med Mol Imaging 2003, 30:682-688.
22. Liedtke M., Hamlin P.A., Moskowitz C.H., Zelenetz A.D. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncology 2006, 17:909-913.
23. Dryver E.T., Jernström H., Tompkins K., Buckstein R., Imrie K.R. Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value. Br J Cancer 2003, 89:482-486.
24. Brenner D.J., Hall E.J. Computed tomography-an increasing source of radiation exposure. N Engl J Med 2007, 357:2277-2284.
25. Cheson B. The case against heavy PETing. J Clin Oncol 2009, 27:1742-1743.
26. Lee A.I., Zuckerman D.S., Van den Abbeele A.D., Aquino S.L., Crowley D., Toomey C., et al. Surveillance imaging of Hodgkin Lymphoma patients in first remission. A clinical and economic analysis. Cancer 2010, 116:3835-3842.
27. Connors J.M. Clinical manifestations and natural history of Hodgkin's lymphoma. Cancer J 2009, 15:124-128.
28. Guppy A.E., Tebbutt N.C., Norman A., Cunningham D. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2003, 44:123-125.